Is cefixime effective for treating Neisseria gonorrhoeae infection?

Cefixime Coverage for Gonorrhea: No Longer Recommended as First-Line Treatment

Cefixime does cover gonorrhea but is no longer recommended as first-line therapy due to rising resistance and treatment failures; it should only be used as an alternative when ceftriaxone is unavailable, and requires mandatory test-of-cure. 1

Current Treatment Landscape

The treatment paradigm for gonorrhea has fundamentally shifted due to antimicrobial resistance. While cefixime historically demonstrated efficacy against Neisseria gonorrhoeae, CDC surveillance data from 2006-2011 showed alarming trends:

• Rising MICs: The percentage of isolates with elevated cefixime MICs (≥0.25 μg/mL) increased from 0.1% in 2006 to 1.4% in 2011, particularly in the Western U.S. and among men who have sex with men 1
• Treatment failures: Clinical failure rates reached 6.77% overall, and 25% when MIC ≥0.12 μg/mL 2
• Geographic variation: Recent Australian data shows 6.3% cefixime resistance, exceeding WHO's 5% threshold 3

Site-Specific Efficacy

Cefixime's effectiveness varies dramatically by anatomic site 4:

Urogenital infections:

• 400 mg single dose: 97% cure rate (95% CI: 96-98%)
• 800 mg single dose: 98% cure rate (95% CI: 96-99%)

Rectal infections:

• 400 mg single dose: 97% cure rate (95% CI: 84-100%)
• Limited data available

Pharyngeal infections:

• 400 mg single dose: Only 89% cure rate (95% CI: 76-96%)
• 800 mg single dose: Only 81% cure rate (95% CI: 61-92%)
• This is the critical weakness—pharyngeal infections are often asymptomatic and facilitate resistance spread

Current Recommendations

First-Line Treatment (Strongly Preferred)

Ceftriaxone 250 mg IM once PLUS azithromycin 1 g PO once (preferred over doxycycline) 1

When Cefixime Must Be Used

Only use cefixime when ceftriaxone is truly unavailable 1:

Regimen: Cefixime 400 mg PO once PLUS azithromycin 1 g PO once (or doxycycline 100 mg PO BID × 7 days)

Mandatory requirements:

• Test-of-cure in 1 week at the infected site 1
• Ideally use culture; if NAAT used and positive, confirm with culture
• All positive cultures require antimicrobial susceptibility testing
• Report treatment failures to CDC within 24 hours

Critical Caveats

Do NOT use cefixime for:

• Pharyngeal gonorrhea as first-line (limited efficacy at 89%) 1, 4
• Patients who may have acquired infection in Asia-Pacific regions (higher resistance) 5
• When local resistance rates exceed 5% 3

Ceftriaxone advantages over cefixime:

• Higher and more sustained bactericidal blood levels 1
• Superior pharyngeal efficacy
• No documented resistance in U.S. strains
• Single IM dose ensures compliance

Why the Downgrade Occurred

The 2012 CDC guidance explicitly removed cefixime from first-line status because 1:

1. Pharmacokinetic inferiority: 400 mg oral cefixime provides lower and less sustained bactericidal levels than 250 mg IM ceftriaxone
2. Resistance trajectory: The pattern mirrors fluoroquinolone resistance emergence (started in West/MSM, then spread nationally)
3. Preservation strategy: Continued cefixime use could accelerate ceftriaxone resistance development
4. Clinical failures: European reports documented treatment failures with 400 mg cefixime 1

FDA-Approved Indication vs. Clinical Reality

Important distinction: The FDA label still lists cefixime as indicated for uncomplicated gonorrhea (cervical/urethral) caused by susceptible N. gonorrhoeae isolates 6. However, CDC guidelines supersede this based on resistance surveillance—a common scenario where real-world resistance patterns outpace label updates.

Practical Algorithm

When treating gonorrhea:

1. First choice: Ceftriaxone 250 mg IM + azithromycin 1 g PO
2. If ceftriaxone unavailable: Cefixime 400 mg PO + azithromycin 1 g PO + schedule test-of-cure in 1 week
3. If severe cephalosporin allergy: Azithromycin 2 g PO + test-of-cure in 1 week 1
4. If treatment failure: Culture with susceptibility testing, consult infectious disease, report to health department, retreat with ceftriaxone 250 mg IM + azithromycin 2 g PO

Always test pharynx in treatment failures, as concurrent asymptomatic pharyngeal infection is common and responds poorly to cefixime 7.

The bottom line: While cefixime retains activity against many gonococcal strains, resistance trends and inferior pharmacokinetics have relegated it to alternative status only. The era of oral cephalosporins as reliable first-line gonorrhea treatment has ended.